Grand Rapids, Mich.-based Spectrum Health signed a risk-based deal with Medtronic to improve outcomes for heart failure patients, the health system said March 31.
The deal will focus on heart patients who receive a cardiac resynchronization therapy device from Medtronic under a financial accountability program. The devices use an algorithm to regularly evaluate a patient's heart rhythm and adjust therapy as needed. In clinical trials, the algorithm has been shown to reduce the risk of 30-day readmissions for heart failure and improve patient survival.
To assess the device's real-world benefits for Spectrum patients, the two organizations will create a program to automatically identify readmissions among this patient population.
Spectrum said it plans to create and launch additional value-based healthcare programs with Medtronic to improve care and lower costs for patients in West Michigan.
To learn more, click here.
More articles on cardiology:
Az. Dignity hospital opens heart arrhythmia center
Heart associations update guidance on heart failure treatment
4 recent heart care partnerships